search
Back to results

Awake Prone Positioning in Moderate to Severe COVID-19

Primary Purpose

COVID-19, SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome

Status
Completed
Phase
Not Applicable
Locations
Vietnam
Study Type
Interventional
Intervention
a wake prone positioning
Sponsored by
Oxford University Clinical Research Unit, Vietnam
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for COVID-19 focused on measuring prone position, severe COVID-19, acute respiratory distress syndrome (ARDS), Vietnam

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Probable or confirmed COVID-19 infection according to WHO criteria
  • Moderate or severe COVID-19 respiratory infection according to Vietnamese guidelines
  • Requirement for supplemental oxygen therapy

Exclusion Criteria:

  • Invasive mechanical ventilation, or non-invasive ventilation (NIV) with CPAP or BiPAP or imminent need for these
  • Contraindications to prone position (see Appendix 5)
  • Pregnancy
  • Severe obesity (BMI >35),
  • Altered level of consciousness (GCS <13)
  • Attending doctor judged prone position to be unsuitable for the patient for any reason
  • Patients in whom there is a decision that care will not be escalated
  • Failure to have informed consent

Sites / Locations

  • Hospital for Tropical Diseases

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

standard care

prone position

Arm Description

Standard care will consist of routine clinical care, including any advice to lie in prone position as routinely recommended by participating sites

prone position group will have a special intervention team who visits patients' rooms aiming for patients to maintain the prone position for at least 8 hours a day

Outcomes

Primary Outcome Measures

Percentage of participants who require escalation of respiratory therapy
Escalation of respiratory therapy within 28 days of randomization, defined as any of the following: Escalation to next level respiratory support (with lowest level nasal cannula or face mask, escalating through HFNC to NIV or mechanical ventilation). Intubation

Secondary Outcome Measures

Fatal event
all-cause of death within first 28 days will be compared between groups
Duration of hospital stay
Days since admission to discharge
Improvement in oxygen related parameters
SpO2, respiratory rate, heart rate, FiO2, ROX index will be documented before and at end of period of prone positioning every day. The improvement will be measured by resolution of them compared with baseline parameters
Number of adverse events
An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. The severity of all AEs in this trial should be graded in line with the toxicity grading in Toxicity grading and management (CTCAE)

Full Information

First Posted
October 10, 2021
Last Updated
June 5, 2023
Sponsor
Oxford University Clinical Research Unit, Vietnam
Collaborators
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
search

1. Study Identification

Unique Protocol Identification Number
NCT05083130
Brief Title
Awake Prone Positioning in Moderate to Severe COVID-19
Official Title
Evaluation of Awake Prone Positioning Effectiveness in Moderate to Severe COVID-19
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
March 8, 2022 (Actual)
Primary Completion Date
March 31, 2023 (Actual)
Study Completion Date
May 1, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Oxford University Clinical Research Unit, Vietnam
Collaborators
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is comparing vital signs between standard care and prone position groups. Standard care will consist of routine clinical care, including any advice to lie in prone position as routinely recommended by participating sites. For those randomized to prone position, a special intervention team will visit patients' rooms aiming for patients to maintain the prone position for at least 8 hours a day.
Detailed Description
This study is a pragmatic open label randomised controlled trial. After being informed about the study and potential risks, all patients having written informed consents will be randomised into two groups. Standard care group will consist of routine clinical care, including any advice to lie in prone position as routinely recommended by participating sites. To reduce bias, the study team will make visits at a similar schedule to those to patients in the intervention group, however these visits will be confined to general advice and measurement of vital signs. Patients will receive written advice more general in nature about COVID-19 disease. For those randomized to prone position group, a special intervention team will visit patients' rooms aiming for patients to maintain the prone position for at least 8 hours a day. The team will give written and verbal advice and if necessary aid patients' positioning themselves in the prone position. The exact duration of prone sessions will be determined according to ward schedules to take account of nursing procedures, meal times and mitigation strategies. Other methods to encourage the maintenance of prone position includes phone calls to patients, carers or education of carers. Compliance with the intervention will be evaluated by observation (manual and using in-room cameras) at fixed time intervals. In a subgroup of 100 patients accelerometer/gyrometer devices will be used to measure movement and position (this will be expanded to all patients if equipment is available). Other outcome measures (SpO2, heart rate etc) will be measured using standard monitoring equipment currently used at study sites, including wearable devices.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19, SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome, Acute Hypoxemic Respiratory Failure, Respiratory Distress Syndrome, Adult
Keywords
prone position, severe COVID-19, acute respiratory distress syndrome (ARDS), Vietnam

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Open label randomised controlled trial comparing standard care to prone position
Masking
None (Open Label)
Allocation
Randomized
Enrollment
93 (Actual)

8. Arms, Groups, and Interventions

Arm Title
standard care
Arm Type
No Intervention
Arm Description
Standard care will consist of routine clinical care, including any advice to lie in prone position as routinely recommended by participating sites
Arm Title
prone position
Arm Type
Experimental
Arm Description
prone position group will have a special intervention team who visits patients' rooms aiming for patients to maintain the prone position for at least 8 hours a day
Intervention Type
Behavioral
Intervention Name(s)
a wake prone positioning
Intervention Description
The team will give written and verbal advice and if necessary aid patients' positioning themselves in the prone position for at least 8 hours per day. The exact duration of prone sessions will be determined according to ward schedules to take account of nursing procedures, meal times and mitigation strategies. Other methods to encourage the maintenance of prone position includes phone calls to patients, carers or education of carers.
Primary Outcome Measure Information:
Title
Percentage of participants who require escalation of respiratory therapy
Description
Escalation of respiratory therapy within 28 days of randomization, defined as any of the following: Escalation to next level respiratory support (with lowest level nasal cannula or face mask, escalating through HFNC to NIV or mechanical ventilation). Intubation
Time Frame
Up to 28 days after enrollment
Secondary Outcome Measure Information:
Title
Fatal event
Description
all-cause of death within first 28 days will be compared between groups
Time Frame
Up to 28 days after enrollment
Title
Duration of hospital stay
Description
Days since admission to discharge
Time Frame
Up to 2 months after enrollment
Title
Improvement in oxygen related parameters
Description
SpO2, respiratory rate, heart rate, FiO2, ROX index will be documented before and at end of period of prone positioning every day. The improvement will be measured by resolution of them compared with baseline parameters
Time Frame
Up to 28 days after enrollment
Title
Number of adverse events
Description
An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. The severity of all AEs in this trial should be graded in line with the toxicity grading in Toxicity grading and management (CTCAE)
Time Frame
Up to 28 days after enrollment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Probable or confirmed COVID-19 infection according to WHO criteria Moderate or severe COVID-19 respiratory infection according to Vietnamese guidelines Requirement for supplemental oxygen therapy Exclusion Criteria: Invasive mechanical ventilation, or non-invasive ventilation (NIV) with CPAP or BiPAP or imminent need for these Contraindications to prone position (see Appendix 5) Pregnancy Severe obesity (BMI >35), Altered level of consciousness (GCS <13) Attending doctor judged prone position to be unsuitable for the patient for any reason Patients in whom there is a decision that care will not be escalated Failure to have informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Louise C Thwaites, MD. PhD.
Organizational Affiliation
University of Oxford, UK
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital for Tropical Diseases
City
Ho Chi Minh City
Country
Vietnam

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Anonymised data of this study may be requested for publication by journals. Sharing anonymised data with future similar/suitable studies will be decided by the sponsor, PIs and the authority agency where the data was collected. No identifiable information will be shared with any other person/organisation
Citations:
PubMed Identifier
32319424
Citation
Dondorp AM, Hayat M, Aryal D, Beane A, Schultz MJ. Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings. Am J Trop Med Hyg. 2020 Jun;102(6):1191-1197. doi: 10.4269/ajtmh.20-0283.
Results Reference
background
PubMed Identifier
34301802
Citation
Gonzalez-Seguel F, Pinto-Concha JJ, Aranis N, Leppe J. Adverse Events of Prone Positioning in Mechanically Ventilated Adults With ARDS. Respir Care. 2021 Dec;66(12):1898-1911. doi: 10.4187/respcare.09194. Epub 2021 Jul 23.
Results Reference
background
PubMed Identifier
34425070
Citation
Ehrmann S, Li J, Ibarra-Estrada M, Perez Y, Pavlov I, McNicholas B, Roca O, Mirza S, Vines D, Garcia-Salcido R, Aguirre-Avalos G, Trump MW, Nay MA, Dellamonica J, Nseir S, Mogri I, Cosgrave D, Jayaraman D, Masclans JR, Laffey JG, Tavernier E; Awake Prone Positioning Meta-Trial Group. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med. 2021 Dec;9(12):1387-1395. doi: 10.1016/S2213-2600(21)00356-8. Epub 2021 Aug 20.
Results Reference
background
Links:
URL
https://doi.org/10.1007/s00134-020-06306-w
Description
Prone position in ARDS patients: why, when, how and for whom. Intensive Care Med [Internet]. 2020;46(12):2385-96.
URL
http://www.ncbi.nlm.nih.gov/pubmed/23688302
Description
Prone positioning in severe acute respiratory distress syndrome. N Engl J Med [Internet]. 2013 Jun 6 [cited 2014 May 23];368(23):2159-68
URL
https://kcb.vn/quyet-dinh-so-4689-qd-byt-ngay-06-10-2021-huong-dan-chan-doan-va-dieu-tri-covid-19-cap-nhat-lan-thu-7.html
Description
Vietnam Ministry of Health guideline on COVID-19 management, treatment
URL
https://doi.org/10.1186/s13054-021-03735-x
Description
Effect of awake prone position on diaphragmatic thickening fraction in patients assisted by noninvasive ventilation for hypoxemic acute respiratory failure related to novel coron
URL
https://doi.org/10.1016/j.bjane.2021.07.029
Description
Effect of early awake prone positioning application on prognosis in patients with acute respiratory failure due to COVID-19 pneumonia: a retrospective observational study. Brazilian J Anesthe
URL
https://doi.org/10.1186/s13054-021-03491-y
Description
Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method. Crit Care [Internet]

Learn more about this trial

Awake Prone Positioning in Moderate to Severe COVID-19

We'll reach out to this number within 24 hrs